Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.46 USD | -2.01% |
|
-0.90% | +14.14% |
| 08:40am | Leerink Partners Adjusts Edwards Lifesciences PT to $87 From $88, Maintains Market Perform Rating | MT |
| 12-05 | Sector Update: Health Care Stocks Lower Late Afternoon | MT |
| Capitalization | 50.02B 43.05B 40.42B 37.57B 69.25B 4,509B 75.55B 471B 182B 2,129B 188B 184B 7,800B | P/E ratio 2025 * |
37.5x | P/E ratio 2026 * | 32x |
|---|---|---|---|---|---|
| Enterprise value | 46.73B 40.22B 37.76B 35.1B 64.7B 4,212B 70.58B 440B 170B 1,989B 175B 172B 7,287B | EV / Sales 2025 * |
7.75x | EV / Sales 2026 * | 6.89x |
| Free-Float |
89.32% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Edwards Lifesciences Corporation
| 1 day | -2.00% | ||
| 1 week | -0.90% | ||
| Current month | -2.50% | ||
| 1 month | +0.50% | ||
| 3 months | +5.35% | ||
| 6 months | +10.66% | ||
| Current year | +14.14% |
| 1 week | 83.6 |  | 87.89 |
| 1 month | 82.01 | | 87.89 |
| Current year | 65.94 | | 87.89 |
| 1 year | 65.94 | | 87.89 |
| 3 years | 58.93 | | 96.12 |
| 5 years | 58.93 | | 131.73 |
| 10 years | 24.07 | | 131.73 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2023-05-10 | |
Scott Ullem
DFI | Director of Finance/CFO | 58 | 2013-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 2019-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 2024-05-06 | |
Kieran Gallahue
BRD | Director/Board Member | 61 | 2015-02-09 |
| Director/Board Member | 57 | 2023-05-10 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.46% | 51 M€ | -2.53% | - |
| 2.34% | 26 M€ | +11.85% | - |
| 1.17% | 27 M€ | +0.66% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.00% | -0.90% | +19.18% | +16.58% | 50.02B | |
| -1.04% | -3.20% | +5.44% | -0.26% | 215B | |
| -1.59% | -0.31% | +4.96% | +107.93% | 204B | |
| -1.22% | -0.31% | -5.29% | -17.80% | 160B | |
| -3.86% | -7.10% | +5.77% | +102.59% | 145B | |
| -0.23% | +1.93% | -17.09% | -12.20% | 56.48B | |
| -2.12% | -5.02% | -0.99% | -8.77% | 41.18B | |
| -2.40% | +5.11% | +1.70% | - | 38.93B | |
| -2.61% | +0.80% | +2.29% | +12.52% | 37.39B | |
| -1.16% | -1.94% | -23.88% | -36.11% | 34.62B | |
| Average | -1.87% | -0.43% | -0.79% | +18.28% | 98.21B | |
| Weighted average by Cap. | -1.80% | -1.12% | +1.48% | +34.92% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.03B 5.19B 4.87B 4.53B 8.35B 544B 9.11B 56.79B 21.99B 257B 22.63B 22.15B 940B | 6.62B 5.7B 5.35B 4.97B 9.16B 597B 10B 62.31B 24.13B 282B 24.84B 24.3B 1,032B |
| Net income | 1.34B 1.15B 1.08B 1.01B 1.86B 121B 2.02B 12.62B 4.89B 57.03B 5.03B 4.92B 209B | 1.57B 1.35B 1.27B 1.18B 2.17B 141B 2.37B 14.75B 5.71B 66.67B 5.88B 5.75B 244B |
| Net Debt | -3.29B -2.83B -2.66B -2.47B -4.56B -297B -4.97B -30.98B -12B -140B -12.35B -12.08B -513B | -4.45B -3.83B -3.6B -3.35B -6.17B -402B -6.73B -41.94B -16.24B -190B -16.71B -16.36B -695B |
Delayed Quote Nyse, December 08, 2025 at 03:01 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition